Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Imagion Biosystems (ASX:IBX) gets ready for Phase 2

It's taken a while to get here, but the US medical device company Imagion Biosystems (ASX: IBX), which listed on the ASX way back in June 2017, is now getting to a really interesting stage of its clinical development, and has just raised $3.5m at 1.5 cents per share to fund this stage. Imagion Biosystems was…

ByNick SundichSeptember 11, 2025

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

When Perth-based Emyria (ASX:EMD) announced on 18 June that Medibank would be funding eligible customer participation in Emyria's Post-Traumatic Stress Disorder care programme, with no out-of-pocket costs, investors who know the Life Sciences sector needed to sit up and take notice. Here was Australia's largest health insurer, with over 4.2 million customers, saying that it…

ByStuart RobertsSeptember 10, 2025

Artrya (ASX:AYA): With FDA 510(k) approval and $75m in fresh capital, its all systems go!

4 years after listing and over 7 years after its founding, Artrya (ASX:AYA) achieved the aspiration of most ASX medtechs, in obtaining FDA approval. Its Salix suite of products aims to improve the detection and treatment of Coronary Artery Disease (CAD), which is a major cause of heart attacks. Entering the US was always this company's…

ByNick SundichSeptember 10, 2025

Telix Pharmaceuticals (ASX:TLX) Gets FDA Green Light to Resubmit — What Investors Should Know

Telix Pharmaceuticals Gains FDA Clarity on Glioma Imaging Agent Telix Pharmaceuticals (ASX: TLX) has given investors reason to sit up and take notice. The company announced it has reached agreement with the U.S. Food and Drug Administration on the resubmission of its new drug application for TLX101-CDx (Pixclara), an imaging agent designed for glioma. What…

ByCharlie YouldenSeptember 9, 2025

Actinogen Medical (ASX:ACW): Will history repeat itself? Can it bounce back from a troublesome Phase 2 trial?

Actinogen Medical (ASX:ACW) is the poster child for how volatile biotech stocks can be. the last time we wrote about this company was in August last year when shares more than halved after results of a Phase II trial that investors perceived to be a flop. But the company has soldiered on and has a…

ByNick SundichSeptember 9, 2025

Imricor Medical Systems (ASX:IMR): Is it the dark horse in the ASX medtech sector?

Imricor Medical Systems (ASX:IMR) is one of a handful of radiology stocks on the ASX, seeking to emulate the success of Pro Medicus (ASX:PME). There's no shortage of peers including Curvebeam AI (ASX:CVB), Resonance Health (ASX:RHT) and 4D Medical (ASX:4DX). But Imricor just might be the dark horse and we're going to tell you why. What…

ByNick SundichSeptember 8, 2025

Argenica Therapeutics (ASX: AGN): A 60% Crash or a Second Chance?

Argenica Therapeutics Just Faced Its Toughest Test — What Comes Next Argenica Therapeutics Ltd (ASX: AGN) has been thrown into the spotlight after its phase 2 trial results for ARG-007 sparked a brutal sell-off, sending the share price tumbling more than 60 percent in a single day. For investors, that kind of market reaction is…

ByCharlie YouldenSeptember 3, 2025

4D Medical (ASX:4DX) could become the next Pro Medicus, and its taken some important strides in 2025!

There's not many Australian radiology companies that seek to conquer the USA, but 4D Medical (ASX:4DX) is one of them. Another one was Pro Medicus (ASX:PME), and everyone knows how that story turned out - that stock is now worth over $11bn, all because of runaway success in the US market. 4D Medical shareholders inevitably…

ByNick SundichSeptember 2, 2025

ASX stocks in America: Here are 4 performing well and 4 performing poorly

You might think ASX stocks in America are doing better than peers which are not there because the USA is a much bigger market. In reality, this is not always the case. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] ASX stocks in America: Here are 4 performing…

ByNick SundichSeptember 2, 2025

Blinklab (ASX:BB1): Is this exciting company the next ResApp?

Blinklab (ASX:BB1) is the answer to the question of how you could help children with autism - a response that begins with 'there's an app for that'. There is precedent for app-based health companies to succeed, just look at ResApp (ASX:RAP), which was bought by Pfizer for $179m back in 2022. The former chairman of that…

ByNick SundichAugust 29, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Imagion Biosystems (ASX:IBX) gets ready for Phase 2

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

Artrya (ASX:AYA): With FDA 510(k) approval and $75m in fresh capital, its all systems go!

Telix Pharmaceuticals (ASX:TLX) Gets FDA Green Light to Resubmit — What Investors Should Know

Actinogen Medical (ASX:ACW): Will history repeat itself? Can it bounce back from a troublesome Phase 2 trial?

Imricor Medical Systems (ASX:IMR): Is it the dark horse in the ASX medtech sector?

Argenica Therapeutics (ASX: AGN): A 60% Crash or a Second Chance?

4D Medical (ASX:4DX) could become the next Pro Medicus, and its taken some important strides in 2025!

ASX stocks in America: Here are 4 performing well and 4 performing poorly

Blinklab (ASX:BB1): Is this exciting company the next ResApp?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here